Compare Novo Nordisk A/S (NVO) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Novo Nordisk A/S trades at $44.75 (market cap $200.69B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $30.4. The key difference: Novo Nordisk A/S pays a 3.98% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none, and Novo Nordisk A/S is trading nearer its 52-week high, Direxion Daily 20 Year Treasury Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| NVO | TMF | |
|---|---|---|
Market Cap | $200.69B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $63.98 | $44.14 |
52-Week Low | $35.29 | $29.83 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
TMF, a leveraged ETF tracking long-term Treasury bonds, trades at $30.85, down 0.13% for the day, with a bearish technical signal driven by moving averages. The stock faces significant long-term erosion, as highlighted by a recent article showing a $10,000 investment five years ago would now be worth about $1,527. Key support lies at $30, with resistance at $31.
The outlook remains challenged by interest rate sensitivity and leverage decay, posing risks for investors seeking Treasury exposure. Opportunities may arise from potential Federal Reserve policy shifts, but volatility and structural ETF risks demand caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
